Roche’s live audio webcast at the 2018 European Society for Medical Oncology (ESMO) Congress Replay
Roche has hosted a live audio webcast and conference call on Monday, 22 October 2018.
| Agenda: | ||
|---|---|---|
| Welcome | Daniel O’Day, CEO Roche Pharmaceuticals | |
| ESMO 2018 Key CIT readouts across tumor types | IMpassion130: Tecentriq + Abraxane in 1L triple-negative breast cancer | Jakob Dupont, M.D., Global Head Breast & Gyn Cancer Franchise, Pharma Development |
| Roche Oncology strategy update | IMpower130: Tecentriq + Abraxane in 1L non-sq NSCLC | BF1RST: Association between bTMB and Tecentriq efficacy in 1L NSCLC ALESIA: Alecensa in 1L ALK+ NSCLC in Asian patients STARTRK2: Entrectinib in NTRK+ solid tumors GO30140: Tecentriq + Avastin in 1L HCC Alan Sandler, M.D., Global Head of Lung/Head & Neck Franchise, Pharma Development, a.i. Global Head Oncology |
| Q&A |